Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / IPAMORELIN
Not FDA-approvedEarly human
Ipamorelin
ALSO KNOWN ASGrowth-hormone secretagogue
A ghrelin-receptor agonist marketed for GH release with major evidence and product-quality gaps.
01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTEMarketed subcutaneously; studied intravenously for postoperative ileus
04REVIEW STANDARDProduct, indication and evidence
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What Ipamorelin is.
A synthetic peptide secretagogue that activates the growth-hormone secretagogue receptor. It is often combined with CJC-1295 despite no approved combination regimen.
HOW IT IS THOUGHT TO WORK
Stimulates pulsatile GH release through the ghrelin receptor, with downstream effects that may include IGF-1 changes.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Can stimulate GH release
- No established muscle, fat-loss, recovery or longevity outcome in healthy consumers
- Safe anti-aging
- Body recomposition
- Sleep improvement
- Benefit of common peptide-clinic stacks
Evidence grade: Early human. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Research interest does not establish an approved treatment, a safe personal regimen or reliable product quality. Discuss established alternatives with a qualified clinician.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- GH or IGF-1 changes alone do not establish benefit
- Glucose, edema and symptoms would require medical oversight
SAFETY
Risks, red flags and reasons to avoid it.
- Immunogenicity and impurity concerns
- Serious adverse events, including death, occurred in an IV gastric-motility study; that route/context differs but underscores uncertainty
- Potential edema, tingling and glucose effects
- Unknown long-term growth-signaling risks
- Self-injection
- Active cancer
- Uncontrolled metabolic disease
- Combining with other secretagogues
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
No FDA-approved ipamorelin product; offered in some compounded and gray-market channels.
Selective GH release is a mechanistic claim. It does not establish a favorable long-term benefit-risk profile for performance or aging.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP